These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 29217530)
1. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA; Haura E; Politi K; Glisson B; Cetnar J; Garon EB; Schiller J; Waqar SN; Sequist LV; Brahmer J; Shyr Y; Kugler K; Wistuba II; Johnson BE; Minna JD; Kris MG; Bunn PA; Kwiatkowski DJ; Clin Cancer Res; 2018 Mar; 24(5):1038-1047. PubMed ID: 29217530 [No Abstract] [Full Text] [Related]
2. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532 [TBL] [Abstract][Full Text] [Related]
3. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Shea M; Costa DB; Rangachari D Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497 [TBL] [Abstract][Full Text] [Related]
4. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland. Grosse A; Grosse C; Rechsteiner M; Soltermann A Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664 [TBL] [Abstract][Full Text] [Related]
5. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042 [TBL] [Abstract][Full Text] [Related]
6. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908 [TBL] [Abstract][Full Text] [Related]
7. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595 [TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. Chun YJ; Choi JW; Hong MH; Jung D; Son H; Cho EK; Min YJ; Kim SW; Park K; Lee SS; Kim S; Kim HR; Cho BC; PLoS One; 2019; 14(11):e0224379. PubMed ID: 31765373 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome. Grosse C; Soltermann A; Rechsteiner M; Grosse A PLoS One; 2019; 14(8):e0220691. PubMed ID: 31386689 [TBL] [Abstract][Full Text] [Related]
10. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China. Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332 [TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220 [TBL] [Abstract][Full Text] [Related]
12. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing. El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Boustany Y; Benmokhtar S; Lamrani Alaoui H; El Annaz H; Abi R; Tagajdid MR; El Kochri S; El Mchichi B; Bouaiti EA; Lahlou IA; El Hassani RA; Ennibi K Technol Cancer Res Treat; 2024; 23():15330338241288907. PubMed ID: 39363851 [TBL] [Abstract][Full Text] [Related]
13. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1. Liu J; Liu Y Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773 [TBL] [Abstract][Full Text] [Related]
14. Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma. Nagahashi M; Sato S; Yuza K; Shimada Y; Ichikawa H; Watanabe S; Takada K; Okamoto T; Okuda S; Lyle S; Takabe K; Tsuchida M; Wakai T J Surg Res; 2018 Oct; 230():181-185. PubMed ID: 30072189 [TBL] [Abstract][Full Text] [Related]
15. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens. Ma Y; Du Y; Wang R; Ji X; Wu J; Liu Y; Guo X; Zhang Y Pathol Res Pract; 2020 Aug; 216(8):153036. PubMed ID: 32703499 [TBL] [Abstract][Full Text] [Related]
16. Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. Tessema M; Rossi MR; Picchi MA; Yingling CM; Lin Y; Ramalingam SS; Belinsky SA Lung Cancer; 2018 Sep; 123():99-106. PubMed ID: 30089603 [TBL] [Abstract][Full Text] [Related]
17. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422 [TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]